Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 10:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 648 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions
Fludarabine, Itacitinib Adipate, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sirolimus, Tacrolimus
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Duarte, California
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Sirolimus
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Renal Cell Carcinoma
Interventions
Combination of Temsirolimus and Sunitinib
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Conditions
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, temozolomide, temsirolimus, bevacizumab, sorafenib, surgery, radiation
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 25 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm
Interventions
Laboratory Biomarker Analysis, Perifosine, Temsirolimus, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
Temsirolimus, Valproic Acid
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina
Conditions
Peutz-Jeghers Syndrome
Interventions
Everolimus
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Melanoma, Colorectal Cancer
Interventions
MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 82 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 3 more
Conditions
Major Depressive Disorder
Interventions
NV-5138
Drug
Lead sponsor
Navitor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Temecula, California
Conditions
Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions
Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI)
Drug · Procedure · Device
Lead sponsor
Vascular Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Huntsville, Alabama • Phoenix, Arizona • Escondido, California + 1 more
Conditions
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Newport Beach, California • Denver, Colorado • Dallas, Texas + 1 more
Active, not recruiting Phase 2 Interventional Results available

Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease

NCT03933904
Conditions
Castleman Disease, Castleman's Disease, Multicentric
Interventions
Sirolimus
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
2 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Little Rock, Arkansas • Philadelphia, Pennsylvania
Conditions
Adult Synovial Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
diagnostic laboratory biomarker analysis, everolimus, imatinib mesylate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prospective Study of Rapamycin for the Treatment of SLE

NCT00779194
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Rapamycin
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Peripheral Pulmonary Stenosis, In-stent Stenosis
Interventions
Sirolimus
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Mesothelioma
Interventions
LMB-100, SEL-110
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Intravenous Daclizumab, Intravenous Infliximab, Observation, Oral Rapamycin
Drug · Other
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years to 92 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
temsirolimus, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
Columbus, Ohio
Conditions
Stem Cell Transplantation
Interventions
tacrolimus, Sirolimus, Methotrexate
Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Recruiting Phase 1 Interventional Accepts healthy volunteers

Effects of Sirolimus on Asymptomatic ApoE4 Carriers

NCT07728175
Conditions
Genetic Predisposition to Disease, Healthy Volunteer, APOE-4 Positive
Interventions
Sirolimus (rapamycin), Placebo
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
bevacizumab, temsirolimus
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee
Conditions
PTEN Gene Mutation, PTEN Hamartoma Tumor Syndrome, PTEN Hamartoma Syndrome
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 45 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Cleveland, Ohio
Conditions
Hodgkin's Lymphoma
Interventions
Temsirolimus
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Conditions
Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Adult T-cell Leukemia/Lymphoma
Interventions
Hyper-CVAD, Sirolimus
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania